Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. (VCYT) is the issuer of common stock that Muna Bhanji plans to sell under Rule 144. The notice covers 3,728 shares of Veracyte common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value listed as $161,012.32 and a proposed sale date of September 1, 2026. The securities to be sold originated from Restricted Stock Units granted by the issuer with an acquisition date of June 18, 2026.
Veracyte reported strong Q2 2026 results, with total revenue rising 15% to $150.3 million, driven by 19% growth in testing revenue to $145.7 million as diagnostic test volume increased 14% to 48,389. Biopharmaceutical and other revenue declined after exiting French contract services.
Gross profit increased to $108.5 million from $89.8 million, and the company generated net income of $25.5 million (diluted EPS $0.31) versus a small loss a year earlier. For the first half of 2026, revenue grew 18% to $289.4 million and net income reached $54.2 million.
Cash, cash equivalents and short-term investments totaled $485.2 million at June 30, 2026, supported by $81.0 million of operating cash flow. Management is increasing research and development spending, especially on the TrueMRD platform and IVD expansion, while noting macroeconomic and reimbursement risks.
Veracyte, Inc. reported total revenue of $150.3 million for the quarter ended June 30, 2026, up 15% from $130.2 million a year earlier. Testing revenue grew 19% to $145.7 million, driven by Decipher prostate testing revenue of $91.9 million and Afirma revenue of $51.2 million. Test volumes increased 13% to 50,967, including 17% growth in Decipher tests to about 29,700 and 10% growth in Afirma tests to about 18,600.
GAAP net income was $25.5 million, a 17.0% margin and an improvement from a prior-year loss, with diluted EPS of $0.31. Non-GAAP gross margin rose to 75% and adjusted EBITDA reached $44.0 million, or 29.2% of revenue. The company generated $45.8 million of operating cash flow and ended the quarter with $485.2 million in cash, cash equivalents and short-term investments.
Management highlighted launches of the Prosigna Breast Test and the TrueMRD Monitoring Test for muscle-invasive bladder cancer, along with Medicare coverage for TrueMRD. Veracyte raised its 2026 total revenue outlook to $590–$596 million and testing revenue guidance to $576–$582 million, and continues to expect adjusted EBITDA margin above 26%.
VERACYTE, INC. director Karin Eastham reported selling 3,729 shares of common stock on June 18, 2026 in open-market transactions. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 5, 2025, at weighted average prices of $52.78 and $53.55 per share.
EASTHAM KARIN reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Karin Eastham received a grant of 5,272 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost and increase her direct holdings to 18,826 shares following the transaction.
The restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the grant date, or immediately before Veracyte’s next annual stockholder meeting if that occurs earlier. They also vest in full if there is a change in control of the company.
VERACYTE, INC. director Evan Jones received an equity award in the form of 5,272 shares of common stock on June 11, 2026, reported as a grant or other acquisition with no purchase price. Following this award, he directly holds 34,634 shares.
The award represents restricted stock units that vest in full on the first anniversary of the grant date or immediately before the company’s next annual stockholder meeting, whichever occurs first. The units also vest in full if there is a change in control of the issuer.
Shafer David Brent reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director David Brent Shafer received a grant of 5,272 restricted stock units on June 11, 2026 as equity compensation. These units vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier, and also fully vest upon a change in control. Following this award, Shafer directly holds 31,100 shares of Veracyte common stock.
Barr Eliav reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Eliav Barr received a grant of 5,272 shares of common stock in the form of restricted stock units. These RSUs were awarded on June 11, 2026 and increase his direct holdings to 56,461 shares. The units vest in full on the first anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, whichever comes first. They also vest in full if there is a change in control of the company.
EPSTEIN ROBERT S reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Robert S. Epstein received an equity award in the form of 5,272 shares of common stock on June 11, 2026. The grant was made at a price of $0.00 per share as compensation rather than an open-market purchase. Following this award, Epstein directly holds 57,718 shares of Veracyte common stock. The underlying restricted stock units vest in full on the first anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders, if earlier, and they also vest in full upon a change in control of the issuer.